www.prnewswire.com ·
protalix biotherapeutics reports first quarter 2026 financial and business results 302770790
Topic context
This topic has been covered 364937 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedProtalix BioTherapeutics reported Q1 2026 results with a significant milestone payment from Chiesi for European approval of Elfabrio dosing regimen. The company's revenue guidance and cash position support ongoing operations and clinical trials. Commercial mechanism is weak: no new supply/demand shock, no margin squeeze, no scarcity. The impact is company-specific and limited to Protalix's pipeline and partnership revenue.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue: $7.4M product sales + $26.3M license/R&D services (incl. $25M milestone from Chiesi).
- 2026 revenue guidance reaffirmed at $78M-$83M.
- Cash and equivalents: $51M as of March 31, 2026.
- Phase 2 RELEASE trial for PRX-115 ongoing; top-line results expected H2 2027.
- R&D expenses rose to $5.4M due to increased clinical trial activity.
Elfabrio (PRX-102) and PRX-115 maintain flat impact in the mid-term; no pricing or margin changes expected within 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
zillow zg q1 2026 earnings 225404880
baptistnews.com
something awful is happening in sudan and you dont know it
cnn.com
trump economy inflation iran gas prices analysis
aktuality.sk
den vitazstva v tieni strachu putin oslavoval bez techniky a v obave z atentatu 217 tyzden vojny
nytimes.com